As of Sep 01
| -17.08 / -3.33%|
The 23 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 607.00, with a high estimate of 720.00 and a low estimate of 500.00. The median estimate represents a +22.28% increase from the last price of 496.42.
The current consensus among 25 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.